Ultragenyx Pharmaceutical (RARE) Current Assets (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Current Assets of $657.0 million for Q1 2026, down 6.03% year-over-year from $699.2 million in Q1 2025, and down 30.91% quarter-over-quarter from $951.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Current Assets (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Current Assets for 14 consecutive years, with $657.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 6.03% year-over-year to $657.0 million; the TTM figure through Mar 2026 stood at $657.0 million (down 6.03% YoY), while the FY2025 annual figure was $951.0 million, up 16.4% from the prior year.
- Current Assets slipped to $657.0 million in Q1 2026 per RARE's latest filing, from $951.0 million in the prior quarter.
- Across five years, Current Assets topped out at $1.0 billion in Q3 2022 and bottomed at $596.0 million in Q1 2024.
- Historically, Current Assets has averaged $760.6 million across 5 years, with a median of $719.8 million in 2025.
- Annual changes were most pronounced in 2023 — Current Assets plunged 40.83% — and 2024, when it jumped 37.39%.
- Ultragenyx Pharmaceutical's Current Assets stood at $883.9 million in 2022, then slipped by 17.16% to $732.2 million in 2023, then climbed by 11.58% to $817.0 million in 2024, then increased by 16.4% to $951.0 million in 2025, then tumbled by 30.91% to $657.0 million in 2026.
- Business Quant data shows RARE's Current Assets at $657.0 million in Q1 2026, $951.0 million in Q4 2025, and $643.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 606.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 606.00 Mn |
| Mar 31, 2026 | 657.00 Mn |
| Dec 31, 2025 | 951.00 Mn |
| Sep 30, 2025 | 643.21 Mn |
| Jun 30, 2025 | 719.79 Mn |
| Mar 31, 2025 | 699.16 Mn |
| Dec 31, 2024 | 817.00 Mn |
| Sep 30, 2024 | 799.61 Mn |
| Jun 30, 2024 | 964.64 Mn |
| Mar 31, 2024 | 595.97 Mn |
| Dec 31, 2023 | 732.18 Mn |
| Sep 30, 2023 | 599.19 Mn |
| Jun 30, 2023 | 702.14 Mn |
| Mar 31, 2023 | 766.34 Mn |
| Dec 31, 2022 | 883.90 Mn |
| Sep 30, 2022 | 1.01 Bn |
| Jun 30, 2022 | 678.54 Mn |
| Mar 31, 2022 | 707.52 Mn |
| Dec 31, 2021 | 856.60 Mn |
| Sep 30, 2021 | 846.88 Mn |